drugset
drugset / Trial / NCT00134355

Study of PTK787 in the Treatment of Patients With Non-Metastatic Androgen Independent Prostate Cancer

NCT00134355 ↗

Phase 2 Completed 5 enrolled University of Michigan Rogel Cancer Center Novartis · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate PTK787/ZK 222584, a drug that blocks new blood vessel growth, in the treatment of patients with non-metastatic androgen independent prostate cancer. This study will assess the safety and tolerability of PTK787/ZK 222584, and evaluate serum vascular endothelial growth factor (VEGF) levels.

Timeline

Start
2005-07
Primary completion
2006-11
Completion
2007-03

Drugs

EvaluationDrugModalityDoseRoute
Subject vatalanib Small molecule 500 mg Oral

Indications

prostate cancer